Updates from the American Society of Clinical Oncology (ASCO) Annual Meeting – Hematology Focus
Description: HOPA is pleased to present the second of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings. In this presentation, we will review key findings from clinical and translational research in hematologic malignancies presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Information highlighted includes recent advances in hematologic malignancies, including new drug approval and new drug indication. By watching this presentation, the audience will gain insight into potential practice-changing outcomes that may impact changes in standard of care practice in these areas.
- Describe the pertinent research in hematologic malignancies presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- Interpret results and conclusions from key abstracts presented at the 2019 ASCO Annual Meeting expected to impact clinical practice
- Demonstrate challenges of novel therapies recently approved or awaiting approval from the FDA in hematologic malignancies including care delivery and discover opportunities to incorporate into clinical practice
Suwicha (Nan) Limvorasak, PharmD BCOP
Disclosure: No financial relationships exist with commercial interests.
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-096-H01-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by August 28, 2022.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% or greater is achieved. Tests must be completed by February 28, 2020.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and managers for the Hematology/Oncology Pharmacy Association do not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs – all faculty will indicate at the start of their presentations if they or will be referencing unlabeled/unapproved uses of drugs and devices.
Individual webinar pricing:
HOPA Member Price: $40 / Non-Member Price: $70